Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • Announced appointment of Mardi C. Dier as Chief Financial Officer • Anticipates resmetirom to become the first medicine approved for NASH; PDUFA date March 14, 2024 • Reports year-end 2023 cash, cash equivalents and marketable securities of $634 million CONSHOHOCKEN, PA, February 28, 2024 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company ...